A Paediatrician’s Fight for ORS Triggers a Larger Debate in the Fraternity

Why It Matters

The dispute underscores the risk of mislabeling health products, which can lead to inappropriate use of sweetened drinks for diarrhoea treatment and erode trust in medical guidance. Clear regulatory and industry distinctions are essential for protecting children and preserving the credibility of pediatric bodies.

Key Takeaways

• Dr. Sivaranjani Santosh resigns from IAP over ORS labeling dispute
• FSSAI banned use of “ORS” label on non‑pharma beverages in Oct 2025
• Kenvue launched ORSL (medical ORS) and eRZL (electrolyte drink) brands
• Experts call for clear public messaging to prevent confusion with sweetened drinks

Pulse Analysis

Oral rehydration salts (ORS) have long been hailed as a lifesaving intervention for childhood diarrhoea, with the World Health Organization setting strict composition standards. In India, the Food Safety and Standards Authority (FSSAI) stepped in last year to curb the misuse of the “ORS” label on beverages that do not meet pharmaceutical criteria, issuing a directive that effectively barred such marketing claims. This regulatory action was driven by concerns that parents might mistake flavored electrolyte drinks for therapeutic ORS, potentially compromising treatment outcomes.

The industry response was swift. Kenvue, the consumer‑health arm of Johnson & Johnson, introduced two distinct product lines: ORSL, marketed explicitly as a WHO‑formulated ORS for medical use, and eRZL, positioned as a general‑purpose electrolyte drink. While Kenvue emphasizes clear packaging and statutory declarations, pediatrician Dr. Santosh contends that the similarity in branding still confuses consumers, especially when eRZL contains sweeteners like sucralose. The tension escalated into a legal notice from Kenvue, reflecting the high stakes of brand differentiation in a market where margins and public health intersect.

Beyond the immediate branding battle, the controversy raises broader questions about the role of professional bodies such as the Indian Academy of Pediatrics. Their recent position paper, which acknowledges WHO‑recommended ORS but also references non‑nutritive sweeteners, has drawn criticism for lacking a consumer‑focused narrative. As pediatric leaders call for unambiguous messaging, the episode may prompt tighter labeling regulations and stronger collaboration between regulators, manufacturers, and medical associations to safeguard vulnerable patients and restore confidence in health‑related product claims.